Trial Profile
Phase I study to determine the maximum tolerated dose of ET-743 (yondelis) [trabectedin] and capecitabine administered to patients with advanced breast cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2006
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Trabectedin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 19 Jan 2006 New trial record.